Field Medical Closes Oversubscribed $35 Million Series B to Advance Development of FieldForce™ Pulsed Field Ablation Platform
— BioStar Capital and Cue Growth co-lead financing to accelerate pivotal trial readiness and expand the ventricular tachycardia (VT) treatment market — New board leadership reflects Field's momentum and readiness for pivotal execution Field Medical, Inc., a clinical-stage company redefining cardiac ablation with next-generation pulsed field ablation (PFA) technology, today announced the close of a […]